The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
ExoU Induces Lung Endothelial Cell Damage and Activates Pro-Inflammatory Caspase-1 during Pseudomonas aeruginosa Infection
Abstract
The Gram-negative, opportunistic pathogen Pseudomonas aeruginosa utilizes a type III secretion system to inject exoenzyme effectors into a target host cell. Of the four best-studied exoenzymes, ExoU causes rapid cell damage and death. ExoU is a phospholipase A2 (PLA2) that hydrolyses host cell membranes, and P. aeruginosa strains expressing ExoU are associated with poor outcomes in critically ill patients with pneumonia. While the effects of ExoU on lung epithelial and immune cells are well studied, a role for ExoU in disrupting lung endothelial cell function has only recently emerged. Lung endothelial cells maintain a barrier to fluid and protein flux into tissue and airspaces and regulate inflammation. Herein, we describe a pulmonary microvascular endothelial cell (PMVEC) culture infection model to examine the effects of ExoU. Using characterized P. aeruginosa strains and primary clinical isolates, we show that strains expressing ExoU disrupt PMVEC barrier function by causing substantial PMVEC damage and lysis, in a PLA2-dependent manner. In addition, we show that strains expressing ExoU activate the pro-inflammatory caspase-1, in a PLA2-dependent manner. Considering the important roles for mitochondria and oxidative stress in regulating inflammatory responses, we next examined the effects of ExoU on reactive oxygen species production. Infection of PMVECs with P. aeruginosa strains expressing ExoU triggered a robust oxidative stress compared to strains expressing other exoenzyme effectors. We also provide evidence that, intriguingly, ExoU PLA2 activity was detectable in mitochondria and mitochondria-associated membrane fractions isolated from P. aeruginosa-infected PMVECs. Interestingly, ExoU-mediated activation of caspase-1 was partially inhibited by reactive oxygen species scavengers. Together, these data suggest ExoU exerts pleiotropic effects on PMVEC function during P. aeruginosa infection that may inhibit endothelial barrier and inflammatory functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ExoU is the most acutely cytotoxic among the four effector proteins because it can induce rapid cell death and is considered to be the main driver of the cytotoxic phenotype.118”
From Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normality Tests for Statistical Analysis: A Guide for Non-Statisticians
Ghasemi, A., & Zahediasl, S. (2012) · International Journal of Endocrinology and Metabolism · doi:10.5812/ijem.3505 · Cited by 4,368
VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease
Kim, J., Gupta, R., Blanco, L. P., Yang, S., Shteinfer-Kuzmine, A., Wang, K., Zhu, J., Yoon, H. E., Wang, X., Kerkhofs, M., et al. (2019) · Science · doi:10.1126/science.aav4011 · Cited by 793 · cited 3×
“To confirm Mito-MAM enrichment in our model, we verified that extracts contained Prohibitin [56,57] and VDAC-1 [58], two known mitochondria-associated control proteins (Figure 3C).”
BackgroundResultPathogenesis of septic shock in Pseudomonas aeruginosa pneumonia
Kurahashi, K., Kajikawa, O., Sawa, T., Ohara, M., Gropper, M. A., Frank, D. W., Martin, T. R., & Wiener-Kronish, J. P. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7124 · Cited by 316
Research works printed but not linked: 72
- Feltman, 2001, Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa, Microbiology, 147, 2659, 10.1099/00221287-147-10-2659 · DOI · Paper page
- Hauser, 2002, Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa, Crit. Care Med., 30, 521, 10.1097/00003246-200203000-00005 · DOI · Paper page
- Savel, 2001, Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections, J. Infect. Dis., 183, 1767, 10.1086/320737 · DOI · Paper page
- Boucher, 2009, Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America, Clin. Infect. Dis., 48, 1, 10.1086/595011 · DOI · Paper page
- Pendleton, 2013, Clinical relevance of the ESKAPE pathogens, Expert Rev. Anti-Infect. Ther., 11, 297, 10.1586/eri.13.12 · DOI · Paper page
- Rice, 2008, Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE, J. Infect. Dis., 197, 1079, 10.1086/533452 · DOI · Paper page
- Frank, 1997, The exoenzyme S regulon of Pseudomonas aeruginosa, Mol. Microbiol., 26, 621, 10.1046/j.1365-2958.1997.6251991.x · DOI · Paper page
- Barbieri, 2000, Pseudomonas aeruginosa exoenzyme S, a bifunctional type-III secreted cytotoxin, Int. J. Med. Microbiol., 290, 381, 10.1016/S1438-4221(00)80047-8 · DOI
- Barbieri, 2004, Pseudomonas aeruginosa ExoS and ExoT, Rev. Physiol. Biochem. Pharmacol., 152, 79, 10.1007/s10254-004-0031-7 · DOI · Paper page
- Goranson, 1997, ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury, Mol. Microbiol., 25, 547, 10.1046/j.1365-2958.1997.4891851.x · DOI · Paper page
- Yahr, 1998, ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system, Proc. Natl. Acad. Sci. USA, 95, 13899, 10.1073/pnas.95.23.13899 · DOI · Paper page
- Anderson, 2011, Ubiquitin and ubiquitin-modified proteins activate the Pseudomonas aeruginosa T3SS cytotoxin, ExoU, Mol. Microbiol., 82, 1454, 10.1111/j.1365-2958.2011.07904.x · doi:10.1111/j.1365-2958.2011.07904.x
- Belyy, 2016, Actin activates Pseudomonas aeruginosa ExoY nucleotidyl cyclase toxin and ExoY-like effector domains from MARTX toxins, Nat. Commun., 7, 13582, 10.1038/ncomms13582 · DOI
- Fu, 1993, The eukaryotic host factor that activates exoenzyme S of Pseudomonas aeruginosa is a member of the 14-3-3 protein family, Proc. Natl. Acad. Sci. USA, 90, 2320, 10.1073/pnas.90.6.2320 · DOI · Paper page
- Housley, 2011, The Rickettsia prowazekii ExoU homologue possesses phospholipase A1 (PLA1), PLA2, and lyso-PLA2 activities and can function in the absence of any eukaryotic cofactors in vitro, J. Bacteriol., 193, 4634, 10.1128/JB.00141-11 · DOI
- Sato, 2006, Identification of superoxide dismutase as a cofactor for the Pseudomonas type III toxin, ExoU, Biochemistry, 45, 10368, 10.1021/bi060788j · DOI
- Allewelt, 2000, Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread, Infect. Immun., 68, 3998, 10.1128/IAI.68.7.3998-4004.2000 · DOI · Paper page
- Hattemer, 2012, Clinical outcomes of type III Pseudomonas aeruginosa bacteremia, Crit. Care Med., 40, 1157, 10.1097/CCM.0b013e3182377906 · DOI
- Schulert, 2003, Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia, J. Infect. Dis., 188, 1695, 10.1086/379372 · doi:10.1086/379372
- Hardy, K.S., Tessmer, M.H., Frank, D.W., and Audia, J.P. (2021). Perspectives on the Pseudomonas aeruginosa Type III Secretion System Effector ExoU and Its Subversion of the Host Innate Immune Response to Infection. Toxins, 13. · DOI
- Diaz, 2010, Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytic cells during acute pneumonia, Infect. Immun., 78, 1447, 10.1128/IAI.01134-09 · DOI
- Frank, 2001, Multiple domains are required for the toxic activity of Pseudomonas aeruginosa ExoU, J. Bacteriol., 183, 4330, 10.1128/JB.183.14.4330-4344.2001 · DOI
- Howell, 2013, Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia, mBio, 4, e00032-13, 10.1128/mBio.00032-13 · doi:10.1128/mbio.00032-13
- Sato, 2004, ExoU is a potent intracellular phospholipase, Mol. Microbiol., 53, 1279, 10.1111/j.1365-2958.2004.04194.x · DOI · Paper page
- Sato, 2003, The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU, EMBO J., 22, 2959, 10.1093/emboj/cdg290 · DOI · Paper page
- Anderson, 2013, Identification of the major ubiquitin-binding domain of the Pseudomonas aeruginosa ExoU A2 phospholipase, J. Biol. Chem., 288, 26741, 10.1074/jbc.M113.478529 · doi:10.1074/jbc.m113.478529
- Pankhaniya, 2004, Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU, Crit. Care Med., 32, 2293, 10.1097/01.CCM.0000145588.79063.07 · DOI
- Shaver, 2004, Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung, Infect. Immun., 72, 6969, 10.1128/IAI.72.12.6969-6977.2004 · DOI · Paper page
- Diaz, 2008, Pseudomonas aeruginosa induces localized immunosuppression during pneumonia, Infect. Immun., 76, 4414, 10.1128/IAI.00012-08 · DOI
- Lins, 2010, ExoU modulates soluble and membrane-bound ICAM-1 in Pseudomonas aeruginosa-infected endothelial cells, Microbes Infect., 12, 154, 10.1016/j.micinf.2009.11.005 · doi:10.1016/j.micinf.2009.11.005
- Pazos, M.A., Lanter, B.B., Yonker, L.M., Eaton, A.D., Pirzai, W., Gronert, K., Bonventre, J.V., and Hurley, B.P. (2017). Pseudomonas aeruginosa ExoU augments neutrophil transepithelial migration. PLoS Pathog., 13. · DOI
- Plotkowski, 2008, Lipid body mobilization in the ExoU-induced release of inflammatory mediators by airway epithelial cells, Microb. Pathog., 45, 30, 10.1016/j.micpath.2008.01.008 · DOI
- Sutterwala, 2007, Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome, J. Exp. Med., 204, 3235, 10.1084/jem.20071239 · DOI · Paper page
- Ferreira, 2015, ExoU-induced redox imbalance and oxidative stress in airway epithelial cells during Pseudomonas aeruginosa pneumosepsis, Med. Microbiol. Immunol., 204, 673, 10.1007/s00430-015-0418-x · DOI
- de Lima, C.D., Calegari-Silva, T.C., Pereira, R.M., Santos, S.A., Lopes, U.G., Plotkowski, M.C., and Saliba, A.M. (2012). ExoU activates NF-kappaB and increases IL-8/KC secretion during Pseudomonas aeruginosa infection. PLoS ONE, 7. · DOI
- Freitas, 2012, The infection of microvascular endothelial cells with ExoU-producing Pseudomonas aeruginosa triggers the release of von Willebrand factor and platelet adhesion, Mem. Inst. Oswaldo Cruz, 107, 728, 10.1590/S0074-02762012000600004 · doi:10.1590/s0074-02762012000600004
- Saliba, 2006, Implications of oxidative stress in the cytotoxicity of Pseudomonas aeruginosa ExoU, Microbes Infect., 8, 450, 10.1016/j.micinf.2005.07.011 · DOI
- Saliba, 2005, Eicosanoid-mediated proinflammatory activity of Pseudomonas aeruginosa ExoU, Cell. Microbiol., 7, 1811, 10.1111/j.1462-5822.2005.00635.x · DOI
- Wagener, B.M., Anjum, N., Christiaans, S.C., Banks, M.E., Parker, J.C., Threet, A.T., Walker, R.R., Isbell, K.D., Moser, S.A., and Stevens, T. (2020). Exoenzyme Y Contributes to End-Organ Dysfunction Caused by Pseudomonas aeruginosa Pneumonia in Critically Ill Patients: An Exploratory Study. Toxins, 12. · doi:10.3390/toxins12060369
- Bouillot, 2015, Pharmacological activation of Rap1 antagonizes the endothelial barrier disruption induced by exotoxins ExoS and ExoT of Pseudomonas aeruginosa, Infect. Immun., 83, 1820, 10.1128/IAI.00010-15 · doi:10.1128/iai.00010-15
- Renema, 2020, Exoenzyme Y induces extracellular active caspase-7 accumulation independent from apoptosis: Modulation of transmissible cytotoxicity, Am. J. Physiol. Lung Cell. Mol. Physiol., 319, L380, 10.1152/ajplung.00508.2019 · DOI
- Alvarez, 2016, Caspase-1 activation protects lung endothelial barrier function during infection-induced stress, Am. J. Respir. Cell Mol. Biol., 55, 500, 10.1165/rcmb.2015-0386OC · DOI
- Renema, 2020, cAMP signaling primes lung endothelial cells to activate caspase-1 during Pseudomonas aeruginosa infection, Am. J. Physiol. Lung Cell. Mol. Physiol., 318, L1074, 10.1152/ajplung.00185.2019 · DOI
- He, 2015, Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion, Cell Res., 25, 1285, 10.1038/cr.2015.139 · DOI · Paper page
- Martinon, 2002, The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta, Mol. Cell, 10, 417, 10.1016/S1097-2765(02)00599-3 · DOI · Paper page
- Shi, 2015, Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death, Nature, 526, 660, 10.1038/nature15514 · DOI · Paper page
- Strowig, 2012, Inflammasomes in health and disease, Nature, 481, 278, 10.1038/nature10759 · DOI · Paper page
- Thornberry, 1992, A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes, Nature, 356, 768, 10.1038/356768a0 · DOI · Paper page
- Lee, 2007, Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU, Infect. Immun., 75, 1089, 10.1128/IAI.01184-06 · DOI
- Morrow, 2016, Pseudomonas aeruginosa exoenzymes U and Y induce a transmissible endothelial proteinopathy, Am. J. Physiol. Lung Cell. Mol. Physiol., 310, L337, 10.1152/ajplung.00103.2015 · DOI
- Schmalzer, 2010, Activation of ExoU phospholipase activity requires specific C-terminal regions, J. Bacteriol., 192, 1801, 10.1128/JB.00904-09 · DOI
- Evavold, 2019, Inflammasomes: Threat-assessment organelles of the innate immune system, Immunity, 51, 609, 10.1016/j.immuni.2019.08.005 · DOI
- Jabir, 2015, Mitochondrial damage contributes to Pseudomonas aeruginosa activation of the inflammasome and is downregulated by autophagy, Autophagy, 11, 166, 10.4161/15548627.2014.981915 · DOI · Paper page
- Elliott, 2018, Cutting Edge: Mitochondrial assembly of the NLRP3 inflammasome complex is initiated at priming, J. Immunol., 200, 3047, 10.4049/jimmunol.1701723 · DOI · Paper page
- Merkwirth, 2009, Prohibitin function within mitochondria: Essential roles for cell proliferation and cristae morphogenesis, Biochim. Biophys. Acta, 1793, 27, 10.1016/j.bbamcr.2008.05.013 · DOI · Paper page
- Anderson, 2015, Ubiquitin activates patatin-like phospholipases from multiple bacterial species, J. Bacteriol., 197, 529, 10.1128/JB.02402-14 · DOI
- Klionsky, 2008, Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes, Autophagy, 4, 151, 10.4161/auto.5338 · DOI · Paper page
- Zhou, 2010, Thioredoxin-interacting protein links oxidative stress to inflammasome activation, Nat. Immunol., 11, 136, 10.1038/ni.1831 · DOI · Paper page
- Zhou, 2011, A role for mitochondria in NLRP3 inflammasome activation, Nature, 469, 221, 10.1038/nature09663 · DOI · Paper page
- Hauser, 1999, Pseudomonas aeruginosa induces type-III-secretion-mediated apoptosis of macrophages and epithelial cells, Infect. Immun., 67, 5530, 10.1128/IAI.67.10.5530-5537.1999 · DOI · Paper page
- Rabin, 2006, A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells, Infect. Immun., 74, 2552, 10.1128/IAI.74.5.2552-2561.2006 · DOI
- Stirling, 2006, Eukaryotic localization, activation and ubiquitinylation of a bacterial type III secreted toxin, Cell. Microbiol., 8, 1294, 10.1111/j.1462-5822.2006.00710.x · doi:10.1111/j.1462-5822.2006.00710.x
- Tyson, 2015, A novel phosphatidylinositol 4,5-bisphosphate binding domain mediates plasma membrane localization of ExoU and other patatin-like phospholipases, J. Biol. Chem., 290, 2919, 10.1074/jbc.M114.611251 · DOI
- Tyson, 2013, Phosphatidylinositol 4,5-bisphosphate is a novel coactivator of the Pseudomonas aeruginosa cytotoxin ExoU, Infect. Immun., 81, 2873, 10.1128/IAI.00414-13 · DOI
- Veesenmeyer, 2010, Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicity, Infect. Immun., 78, 3346, 10.1128/IAI.00223-10 · doi:10.1128/iai.00223-10
- Broz, 2013, Measuring inflammasome activation in response to bacterial infection, Methods Mol. Biol., 1040, 65, 10.1007/978-1-62703-523-1_6 · DOI
- Bagayoko, S., Leon-Icaza, S.A., Pinilla, M., Hessel, A., Santoni, K., Pericat, D., Bordignon, P.J., Moreau, F., Eren, E., and Boyance, A. (2021). Host phospholipid peroxidation fuels ExoU-dependent cell necrosis and supports Pseudomonas aeruginosa-driven pathology. PLoS Pathog., 17. · doi:10.1101/2021.02.17.431580
- Pendyala, 2009, Role of Nox4 and Nox2 in hyperoxia-induced reactive oxygen species generation and migration of human lung endothelial cells, Antioxid. Redox Signal., 11, 747, 10.1089/ars.2008.2203 · DOI · Paper page
- Sawa, 1999, Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury, Nat. Med., 5, 392, 10.1038/7391 · DOI · Paper page
- Vallis, 1999, Biological effects of Pseudomonas aeruginosa type III-secreted proteins on CHO cells, Infect. Immun., 67, 2040, 10.1128/IAI.67.4.2040-2044.1999 · DOI
- Audia, J.P., Lindsey, A.S., Housley, N.A., Ochoa, C.R., Zhou, C., Toba, M., Oka, M., Annamdevula, N.S., Fitzgerald, M.S., and Frank, D.W. (2013). In the absence of effector proteins, the Pseudomonas aeruginosa type three secretion system needle tip complex contributes to lung injury and systemic inflammatory responses. PLoS ONE, 8. · DOI
- Benson, 2010, A sensitive fluorescence-based assay for the detection of ExoU-mediated PLA2 activity, Clin. Chim. Acta, 411, 190, 10.1016/j.cca.2009.10.025 · doi:10.1016/j.cca.2009.10.025
Cited by
Qin, S., Xiao, W., Zhou, C., Pu, Q., Deng, X., Lan, L., Liang, H., Song, X., & Wu, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01056-1 · Cited by 1,703
Metadata
- Authors
- Hardy, K. S., Tuckey, A. N., Renema, P., Patel, M., Al-Mehdi, A.-B., Spadafora, D., Schlumpf, C. A., Barrington, R. A., Alexeyev, M. F., Stevens, T., Pittet, J.-F., Wagener, B. M., Simmons, J. D., Alvarez, D. F., & Audia, J. P.
- Affiliations
- Department of Microbiology and Immunology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA
- Center for Lung Biology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA
- Flow Cytometry Core Lab, College of Medicine, University of South Alabama, Mobile, AL 36688, USA
- Department of Anesthesiology and Perioperative Medicine, Birmingham School of Medicine, University of Alabama, Birmingham, AL 35294, USA
- Venue
- Toxins
- Publisher
- MDPI AG
- Published
- 2022-02-18
- Volume
- 14
- Issue
- 2
- Pages
- 152
- ISSN
- 2072-6651
- Cited by
- 21
- References
- 3
- Language
- en
- Funders
- National Heart Lung and Blood Institute (HL118334, HL118334-S1)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ExoU Induces Lung Endothelial Cell Damage and Activates Pro-Inflammatory Caspase-1 during Pseudomonas aeruginosa Infection. https://app.cochat.ai/papers/10.3390/toxins14020152
- The paper
- Hardy, K. S., Tuckey, A. N., Renema, P., Patel, M., Al-Mehdi, A.-B., Spadafora, D., Schlumpf, C. A., Barrington, R. A., Alexeyev, M. F., Stevens, T., Pittet, J.-F., Wagener, B. M., Simmons, J. D., Alvarez, D. F., & Audia, J. P. (2022). ExoU Induces Lung Endothelial Cell Damage and Activates Pro-Inflammatory Caspase-1 during Pseudomonas aeruginosa Infection. Toxins. https://doi.org/10.3390/toxins14020152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.